Tumor Necrosis Factor α Activation of the Apoptotic Cascade in Murine Articular Chondrocytes Is Associated with the Induction of Metalloproteinases and Specific Pro-Resorptive Factors

Arthritis and Rheumatism

Volumn 48, Issue 10, 2003, Pages 2845-2854

  Cho, Tae Joon ^a,b   Lehmann, Wolfgang ^a,c   Edgar, Cory ^a   Sadeghi, Cameron ^a   Hou, Andrew ^a   Einhorn, Thomas A ^a   Gerstenfeld, Louis C ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DNA; MESSENGER RNA; METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; APOPTOSIS; ARTHRITIS; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CELL DEATH; DNA CONTENT; ENZYME INDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOPROTEINS; MACROPHAGE COLONY-STIMULATING FACTOR; MATRIX METALLOPROTEINASE 3; MICE; MICE, MUTANT STRAINS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; OSTEOPROTEGERIN; PHENOTYPE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0142135684     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.11390     Document Type: Article

References (40)

1. Butler DM, Malfait AM, Mason LJ, Warden PJ, Kollias G, Maini RN, et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. J Immunol 1997;159:2867-76.
2. Maini RN, Elliott MJ, Brennan FM, Feldmann M. Beneficial effects of tumor necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 1995;101:207-12.
3. Maini RN, Feldmann M. How does infliximab work in rheumatoid arthritis? Arthritis Res 2002;4 Suppl 2:S22-8.
4. Maini RN, Taylor PC. Anti-cytokine therapy in rheumatoid arthritis. Annu Rev Med 2000;51:207-29.
5. Lipsky PE, van der Heidje DMFM, William SCE, Furst D, Breedveld F, Kalden J, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
6. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
7. Feldmann M, Maini RN. Anti-TNF - a therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96.
8. Fraser A, Fearon U, Reece R, Emery P, Veale DJ. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001;9:2024-8.
9. Freemont AJ, Hampson V, Tilman R, Goupille P, Taiwo Y, Hoyland JA. Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific. Ann Rheum Dis 1997;56:542-9.
10. Jain A, Nanchahal J, Troeberg L, Green P, Brennan F. Production of cytokines, vascular endothelial growth factor, matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by tenosynovium demonstrates its potential for tendon destruction in rheumatoid arthritis. Arthritis Rheum 2001;44:1754-60.
11. Aizawa T, Kon T, Einhorn TA, Gerstenfeld LC. Induction of apoptosis in chondrocytes by tumor necrosis factor-alpha. J Orthop Res 2001;19:785-96.
12. Gerstenfeld LC, Cho T-J, Kon T, Aizawa T, Tsay A, Barnes GL, et al. Impaired fracture healing in the absence of tumor necrosis factor-α signaling. J Bone Miner Res 2003;18:1584-92.
13. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factor alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987;138:775-9.
14. Kimble RB, Bain S, Pacifici R. The functional block of TNF but not IL-6 prevents bone loss in ovariectomized mice. J Bone Miner Res 1997;12:935-41.
15. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160:943-52.
16. Ranger AM, Gerstenfeld LC, Wang J, Kon T, Bae H, Gravallese EM, et al. The nuclear factor of activated T cells (NFAT) transcription factor NFATp (NFATc2) is a repressor of chondrogenesis. J Exp Med 2000;191:9-22.
17. Gerstenfeld LC, Finer MH, Boedtker H. Quantitative analysis of collagen expression in embryonic chick chondrocytes having different developmental fates. J Biol Chem 1989;264:5112-20.
18. Toma CD, Ashkar S, Gray ML, Schaffer JL, Gerstenfeld LC. Signal transduction of mechanical stimuli is dependent on microfilament integrity: identification of osteopontin as a mechanically induced gene in osteoblasts. J Bone Miner Res 1997;12:1626-36.
19. Thomas PS. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci U S A 1980;77:5201-5.
20. Sandell LJ, Nalin AM, Reife RA. Alternative splice form of type II procollagen mRNA (IIA) is predominant in skeletal precursors and non-cartilaginous tissues during early mouse development. Dev Dyn 1994;199:129-40.
21. Cho T-J, Gerstenfeld LC, Einhorn TA. Differential temporal expression of members of the transforming growth factor-beta superfamily during murine fracture healing. J Bone Miner Res 2002;17:513-20.
22. Lian JB, Stein GS, Stein JL, van Wijnen AJ. Osteocalcin gene promoter: unlocking the secrets for regulation of osteoblast growth and differentiation. J Cell Biochem Suppl 1998;30-31:62-72.
23. De Bri E, Reinholt FP, Heinegard D, Mengarelli-Widholm S, Norgard M, Svensson O. Bone sialoprotein and osteopontin distribution at the osteocartilaginous interface. Clin Orthop 1996;330:251-60.
24. Shen Z, Heinegard D, Sommarin Y. Distribution and expression of cartilage oligomeric matrix protein and bone sialoprotein show marked changes during rat femoral head development. Matrix Biol 1995;14:773-81.
25. Gerstenfeld LC, Cho T-J, Kon T, Aizawa T, Cruceta J, Graves BD, et al. Impaired intramembranous bone formation during bone repair in the absence of tumor necrosis factor-alpha signaling. Cells Tissues Organs 2001;169:285-94.
26. Blanco FJ, Ochs RL, Schwarz H, Lotz M. Chondrocyte apoptosis induced by nitric oxide. Am J Pathol 1995;146:75-85.
27. Hashimoto S, Setareh M, Ochs RL, Lotz M. Fas/Fas ligand expression and induction of apoptosis in chondrocytes. Arthritis Rheum 1997;40:1749-55.
28. Green DR, Ferguson TA. The role of Fas ligand in immune privilege. Nat Rev Mol Cell Biol 2001;2:917-24.
29. Sakai T, Kambe F, Mitsuyama H, Ishiguro N, Kurokouchi K, Takigawa M, et al. Tumor necrosis factor alpha induces expression of genes for matrix degradation in human chondrocyte-like HCS-2/8 cells through activation of NF-kappaB: abrogation of the tumor necrosis factor alpha effect by proteasome inhibitors. J Bone Miner Res 2001;16:1272-80.
30. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000;43:852-8.
31. Posthumus MD, Limburg PC, Westra J, Cats HA, Stewart RE, van Leeuwen MA, et al. Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford) 1999;38:1081-7.
32. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997;36:643-50.
33. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
34. Komuro H, Olee T, Kühn K, Quach J, Brinson DC, Shikhman A, et al. The osteoprotegerin/receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand system in cartilage. Arthritis Rheum 2001;44:2768-76.
35. Feuerherm AJ, Borset M, Seidel C, Sundan A, Leistad L, Ostensen M, et al. Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand J Rheumatol 2001;30:229-34.
36. Studer R, Jaffurs D, Stefanovic-Racic M, Robbins PD, Evans CH. Nitric oxide in osteoarthritis. Osteoarthritis Cartilage 1999;7:377-9.
37. Armour KJ, Armour KE, van't Hof RJ, Reid DM, Wei X-Q, Liew FY, et al. Activation of the inducible nitric oxide synthase pathway contributes to inflammation-induced osteoporosis by suppressing bone formation and causing osteoblast apoptosis. Arthritis Rheum 2001;44:2790-6.
38. Maier R, Bilbe G, Rediske J, Lotz M. Inducible nitric oxide synthase from human articular chondrocytes: cDNA cloning and analysis of mRNA expression. Biochim Biophys Acta 1994;1208:145-50.
39. Vuolteenaho K, Moilanen T, Al-Saffar N, Knowles RG, Moilanen E. Regulation of the nitric oxide production resulting from the glucocorticoid-insensitive expression of iNOS in human osteoarthritic cartilage. Osteoarthritis Cartilage 2001;9:597-605.
40. Melchiorri C, Meliconi R, Frizziero L, Silvestri T, Pulsatelli L, Mazzetti I, et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998;41:2165-74.